文献速递胸部肿瘤

强PD-L1表达预测EGFR突变NSCLC对EGFR-TKI反应差及原发耐药

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
PubMed 文献 · J Thorac Oncol · 2018-07-26

该回顾性研究纳入101例接受EGFR-TKI治疗的EGFR突变晚期NSCLC患者,同时评估PD-L1状态。强PD-L1表达者客观缓解率显著降低(35.7%对63.2%对67.3%,p=0.002),无进展生存期缩短(3.8对6.0对9.5个月,p<0.001),且原发耐药者PD-L1阳性比例更高(66.7%对30.2%,p=0.009)。

要点

  • 强PD-L1表达与EGFR-TKI客观缓解率降低和PFS缩短显著相关
  • PD-L1阳性在原发耐药者中比获得性耐药者更常见(66.7%对30.2%)
  • 原发耐药者中PD-L1与CD8双阳性比例达46.7%(7/15)

核心结论

  • PD-L1表达对EGFR-TKI疗效有不良影响,尤其在原发耐药的EGFR突变NSCLC患者中。
  • 研究提示PD-L1与CD8双阳性重塑炎症免疫表型,可能对PD-1阻断治疗敏感。

研究设计与样本

  • 回顾性研究纳入2016年4月至2017年9月在广东省肺癌研究所接受EGFR-TKI治疗的晚期NSCLC患者101例,排除临床试验入组者。
  • 同时评估患者EGFR和PD-L1状态。

主要发现

  • 强PD-L1表达者客观缓解率显著低于弱表达和阴性表达者(35.7%对63.2%对67.3%,p=0.002)。
  • 强PD-L1表达者无进展生存期显著缩短(3.8对6.0对9.5个月,p<0.001),与EGFR突变类型(19del或L858R)无关。
  • PD-L1阳性在原发耐药者中占比高于获得性耐药者(66.7%对30.2%,p=0.009)。
  • 原发耐药者中PD-L1与CD8双阳性比例为46.7%(7/15)。
  • 1例原发耐药且PD-L1与CD8双阳性患者对抗PD-1治疗反应良好。

临床怎么用

  • 对EGFR突变NSCLC患者,可考虑同时评估PD-L1状态以辅助预测EGFR-TKI疗效。
  • 原发耐药且PD-L1与CD8双阳性者,或可考虑PD-1阻断治疗。

局限性

  • 回顾性研究,样本量101例,来自单中心。
  • 未报告多因素校正分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study evaluated whether tumor expression of programmed death ligand 1 (PD-L1) could predict the response of EGFR-mutated NSCLC to EGFR tyrosine kinase inhibitor (TKI) therapy. METHODS: We retrospectively evaluated patients who received EGFR-TKIs for advanced NSCLC at the Guangdong Lung Cancer Institute between April 2016 and September 2017 and were not enrolled in clinical studies. The patients' EGFR and PD-L1 statuses were simultaneously evaluated. RESULTS: Among the 101 eligible patients, strong PD-L1 expression significantly decreased objective response rate, compared with weak or negative PD-L1 expression (35.7% versus 63.2% versus 67.3%, p = 0.002), and shortened progression-free survival (3.8 versus 6.0 versus 9.5 months, p < 0.001), regardless of EGFR mutation type (19del or L858R). Furthermore, positive PD-L1 expression was predominantly observed among patients with de novo resistance rather than acquired resistance to EGFR-TKIs (66.7% versus 30.2%, p = 0.009). Notably, we found a high proportion of PD-L1 and cluster of differentiation 8 (CD8) dual-positive cases among patients with de novo resistance (46.7%, 7 of 15). Finally, one patient with de novo resistance to EGFR-TKIs and PD-L1 and CD8 dual positivity experienced a favorable response to anti-programmed death 1 therapy. CONCLUSIONS: This study revealed the adverse effects of PD-L1 expression on EGFR-TKI efficacy, especially in NSCLC patients with de novo resistance. The findings indicate the reshaping of an inflamed immune phenotype characterized by PD-L1 and CD8 dual positivity and suggest potential therapeutic sensitivity to programmed death 1 blockade.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Su S, Dong ZY, Xie Z, et al. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol. 2018. PMID: 30056164. doi:10.1016/j.jtho.2018.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。